ALB and Alzheimer disease: To fill this gap, in the present work, we systematically search for the clinically approved low-molecular-weight ligands (LMWLs) in HSA related to AD progression that could modify HSA affinity for Aβ, and selectively test the candidate ligands from this perspective after their careful structural systematization and ranking.